Immucell's biggest risks in the FY2024 10-K
- Re-Tain® commercialization depends on FDA approval, funding, customer adoption, and reliable contract manufacturing.
- First Defense® generated 99% of product sales, with 86% of sales concentrated among U.S. dairy and beef customers.
- Production contamination, equipment failures, debt covenants, PFAS rules, and supply access create operational pressure.
The risks most specific to Immucell
- Financial Risks
Risks associated with our funding strategy for Re-Tain®
Insufficient cash and liquidity could prevent commercialization of Re-Tain®, whose FDA approval depends on commercial-scale pharmaceutical-grade Nisin.
- Product Risks
Contamination events, equipment failures and gross margin from our production process
Contamination events and equipment failures disrupted production, caused inventory scrap, and materially harmed operating results during 2022–2024.
- Product Risks
1) A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from cows being treated with Re-Tain®, when tested randomly for inhibitors by a milk hauler, which could create legal liability
Re-Tain® residues could cause milk-inhibitor rejections or failed cheese tanks, creating customer losses and potential legal liability.
- Product Risks
6) Producers either do not choose to use it or might use it improperly, rather than follow our label instructions to administer one dose after each of three consecutive milkings, or they may limit use within the herd in an abundance of caution to avoid the negative outcomes described above
Producers may avoid or misuse Re-Tain®, while the DP filling agreement expired in November 2024 and inventory may only last into early 2026.
- Product Risks
Concentration of sales
First Defense® represented 99% of product sales, with 86% of sales coming from U.S. dairy and beef customers.
- Regulatory Risks
Regulatory requirements for Re-Tain®
Re-Tain® cannot launch commercially without FDA approval, and its NADA review has already taken approximately 17 years.
- Regulatory Risks
Regulatory requirements limiting access to suppliers and customer base
Maine’s phased PFAS restrictions could limit suppliers, products, or customer access for the company’s manufacturing operations.
- Regulatory Risks
Reliance on outside party to provide certain services under contract for us
Re-Tain® depends on subcontractors such as Norbrook meeting regulatory requirements and providing required manufacturing services.
- Other Risks
Access to raw materials and contract manufacturing services
Third-party supply disruptions could restrict essential components, testing materials, and colostrum purchased from farms for First Defense®.
- Financial Risks
Debt covenants
Debt covenants require a 1.35 minimum DSC ratio, while actual ratios were below that level in 2022–2024.
All 42 risk factors
Headings as the filing states them, in filing order.
Other
- 01OUTLINE TO ITEM 1A – RISK FACTORS
Financial Risks
- 02Gross margin on product sales
- 03Exposure to interest rates and debt service obligations
- 04Debt covenants
- 05Currency exchange fluctuation
- 06Inflation, supply disruptions, tax rates and economic downturns
- 07Projection of net (loss) income
- 08Risks associated with our funding strategy for Re-Tain®
- 09Uncertainty of market size and product sales estimates
- 10Net deferred tax assets
Product Risks
- 11Product risks generally
- 12Contamination events, equipment failures and gross margin from our production process
- 13Sales risks pertaining to Re-Tain®
- 141) A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from cows being treated with Re-Tain®, when tested randomly for inhibitors by a milk hauler, which could create legal liability
- 156) Producers either do not choose to use it or might use it improperly, rather than follow our label instructions to administer one dose after each of three consecutive milkings, or they may limit use within the herd in an abundance of caution to avoid the negative outcomes described above
- 16Reliance on sales of the First Defense® product line
- 17Concentration of sales
- 18Production capacity constraints
- 19Product liability
Regulatory Risks
- 20Regulatory requirements for the First Defense® product line
- 21Regulatory requirements for Re-Tain®
- 22Regulatory requirements limiting access to suppliers and customer base
- 23Immigration
- 24Cattle count
- 25Herd size
- 26Milk cow price
- 27Milk price
- 28Feed Costs
- 29Volatility of the dairy market
- 30Dependence on key personnel
- 31Reliance on outside party to provide certain services under contract for us
- 32Competition from others
Global Risks
- 33Tariffs and Trade Policies
- 34International Conflicts
- 35Climate change
- 36Bovine diseases
- 37Stock market valuation and liquidity
- 38No expectation to pay any dividends or repurchase stock for the foreseeable future
- 39Possible dilution
Other Risks
- 40Access to raw materials and contract manufacturing services
- 41Failure to protect intellectual property
- 42Increasing dependence on the continuous and reliable operation of our information technology systems
Other Immucell 10-Ks
- FY2025 10-K risk factors36 risks6 new12 dropped19 reworded
Re-Tain® strategy shifted from internal manufacture toward licensing, sale, or partnership after abandoning planned production.
Filed Mar 30, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.